Dasari A, Shen C, Halperin D, et al (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3:1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589

Article  PubMed  PubMed Central  Google Scholar 

Nuñez-Valdovinos B, Carmona‐Bayonas A, Jimenez‐Fonseca P, et al (2018) Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real‐World Data from the Spanish Tumor Registry (R‐GETNE). The Oncologist 23:422–432. https://doi.org/10.1634/theoncologist.2017-0364

White BE, Rous B, Chandrakumaran K, et al (2022) Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. Lancet Reg Health - Eur 23:100510. https://doi.org/10.1016/j.lanepe.2022.100510

Article  PubMed  PubMed Central  Google Scholar 

Rindi G, Mete O, Uccella S, et al (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33:115–154. https://doi.org/10.1007/s12022-022-09708-2

Article  PubMed  Google Scholar 

de Mestier L, Lepage C, Baudin E, et al (2020) Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 52:473–492. https://doi.org/10.1016/j.dld.2020.02.011

Article  PubMed  Google Scholar 

Kos-Kudła B, Castaño JP, Denecke T, et al (2023) European Neuroendocrine Tumor Society 2023 Guidance Paper for Non‐functioning Pancreatic Neuroendocrine Tumours. J Neuroendocrinol e13343. https://doi.org/10.1111/jne.13343

Dilz L-M, Denecke T, Steffen IG, et al (2015) Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 51:1253–1262. https://doi.org/10.1016/j.ejca.2015.04.005

Article  PubMed  Google Scholar 

de Mestier L, Walter T, Brixi H, et al (2019) Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. Neuroendocrinology 108:343–353. https://doi.org/10.1159/000498887

Article  PubMed  Google Scholar 

Kunz PL, Graham NT, Catalano PJ, et al (2023) Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol 41:1359–1369. https://doi.org/10.1200/JCO.22.01013

Article  PubMed  Google Scholar 

de Mestier L, Couvelard A, Blazevic A, et al (2020) Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocr Relat Cancer 27:R391–R405. https://doi.org/10.1530/ERC-20-0227

Article  PubMed  Google Scholar 

Alexandraki KI, Spyroglou A, Kykalos S, et al (2021) Changing biological behaviour of NETs during the evolution of the disease: progress on progression. Endocr Relat Cancer 28:R121–R140. https://doi.org/10.1530/ERC-20-0473

Article  PubMed  Google Scholar 

Bourdeleau P, Couvelard A, Ronot M, et al (2023) Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms. Ther Adv Med Oncol 15:175883592311793. https://doi.org/10.1177/17588359231179310

Article  Google Scholar 

Botling J, Lamarca A, Bajic D, et al (2020) High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 110:891–898. https://doi.org/10.1159/000504392

Article  PubMed  Google Scholar 

Bourdeleau P, Pokossy-Epée J, Hentic O, et al (2025) Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours. Endocr Relat Cancer 32:e240321. https://doi.org/10.1530/ERC-24-0321

Article  PubMed  Google Scholar 

Mollazadegan K, Botling J, Skogseid B, et al (2025) The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study. J Neuroendocrinol e70040. https://doi.org/10.1111/jne.70040

Article  Google Scholar 

Kasajima A, Pfarr N, Mayr E-M, et al (2024) Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation. Endocr Pathol 35:313–324. https://doi.org/10.1007/s12022-024-09827-y

Article  PubMed  PubMed Central  Google Scholar 

Mete O (2024) Insights into Biologic Evolution of Grade 3 Neuroendocrine Tumors Reflect Classification Challenges. Endocr Pathol 35:311–312. https://doi.org/10.1007/s12022-024-09844-x

Article  PubMed  Google Scholar 

Joseph NM, Umetsu SE, Kim GE, et al (2024) Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocr Pathol 35:325–337. https://doi.org/10.1007/s12022-024-09835-y

Article  PubMed  PubMed Central  Google Scholar 

Touat M, Li YY, Boynton AN, et al (2020) Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:517–523. https://doi.org/10.1038/s41586-020-2209-9

Article  PubMed  PubMed Central  Google Scholar 

de Mestier L, Cohen D, Masliah Planchon J, et al (2023) Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors (1182O). Ann Oncol 34 (suppl.2):S701–S710. https://doi.org/10.1016/S0923-7534(23)01264-4

Article  Google Scholar 

Backman S, Botling J, Nord H, et al (2024) The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation. J Pathol 264:357–370. https://doi.org/10.1002/path.6348

Article  PubMed  Google Scholar 

Crisafulli G, Sartore-Bianchi A, Lazzari L, et al (2022) Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov candisc.1434.2021. https://doi.org/10.1158/2159-8290.CD-21-1434

Article  Google Scholar 

Mehnert JM, Bergsland E, O’Neil BH, et al (2020) Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer 126:3021–3030. https://doi.org/10.1002/cncr.32883

Article  PubMed  Google Scholar 

Strosberg J, Mizuno N, Doi T, et al (2020) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res 26:2124–2130. https://doi.org/10.1158/1078-0432.CCR-19-3014

Article  PubMed  PubMed Central  Google Scholar 

Yao JC, Strosberg J, Fazio N, et al (2021) Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer ERC-20-0382.R1. https://doi.org/10.1530/ERC-20-0382

Article  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  PubMed  Google Scholar 

Klein O, Kee D, Markman B, et al (2020) Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clin Cancer Res 26:4454–4459. https://doi.org/10.1158/1078-0432.CCR-20-0621

Article  PubMed  Google Scholar 

Patel SP, Othus M, Chae YK, et al (2020) A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res 26:2290–2296. https://doi.org/10.1158/1078-0432.CCR-19-3356

Article  PubMed  PubMed Central  Google Scholar 

Morano F, Raimondi A, Pagani F, et al (2022) Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6 -Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial. J Clin Oncol 40:1562–1573. https://doi.org/10.1200/JCO.21.02583

Article  PubMed  PubMed Central  Google Scholar 

Germano G, Lamba S, Rospo G, et al (2017) Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552:116–120. https://doi.org/10.1038/nature24673

Article  PubMed  Google Scholar 

Lamarca A, Barriuso J, McNamara MG, et al (2020) Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. Neuroendocrinology 110:155–157. https://doi.org/10.1159/000503392

Article  PubMed  Google Scholar 

Trevisani E, Cingarlini S, Taboada RG, et al (2024) 1154P Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI). Ann Oncol 35:S755. https://doi.org/10.1016/j.annonc.2024.08.1213

Article  Google Scholar 

Indraccolo S, Lombardi G, Fassan M, et al (2019) Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clin Cancer Res 25:1828–1837. https://doi.org/10.1158/1078-0432.CCR-18-1892